

## Review Form 1.7

|                          |   |
|--------------------------|---|
| Journal Name:            | International Journal of Biochemistry Research & Review |
| Manuscript Number:       | Ms_IJBCRR_116089  |
| Title of the Manuscript: | CANCER: IMMUNOLOGY AND IMMUNOTHERAPY                    |
| Type of the Article      | Review Article  |

### PART 1: Review Comments

|   | Reviewer's comment  | Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here) |
|---|---|---|
| <b>Compulsory</b> REVISION comments<br><br>1. <b>Is the manuscript important for scientific community?</b><br>(Please write few sentences on this manuscript)<br><br>2. <b>Is the title of the article suitable?</b><br>(If not please suggest an alternative title)<br><br>3. <b>Is the abstract of the article comprehensive?</b><br><br>4. <b>Are subsections and structure of the manuscript appropriate?</b><br><br>5. <b>Do you think the manuscript is scientifically correct?</b><br><br>6. <b>Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form.</b><br><br><u>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</u> | Yes, the author provides the basics of cancer immunology and immunotherapy<br><br>Yes<br><br>Yes<br><br>Yes<br><br>Yes<br><br>Yes   |   |
| <b>Minor</b> REVISION comments<br><br>1. <b>Is language/English quality of the article suitable for scholarly communications?</b>   | Yes   |   |
| <b>Optional/General</b> comments  | I recommend accept with changes that include; The author is advised to discuss the limited overall responses only 20-30% and lack of reliable predictive biomarker of patient's response and major pitfalls that limits its success. Extend discussion to BTLA/HVEM axis dysregulation that is linked to poor prognosis in solid and haematological malignancies. Discuss trials of anti-BTLA antibodies. Discuss TIM-3 immunoregulatory role and its interactions. |   |

Review Form 1.7

**PART 2:**

|   |  |   |
|---|--|---|
|   | <b>Reviewer’s comment</b>  | <b>Author’s comment</b> <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i> |
| <b>Are there ethical issues in this manuscript?</b> | <i>(If yes, Kindly please write down the ethical issues here in details)</i> |   |

**Reviewer Details:**

|                                  |                                    |
|----------------------------------|------------------------------------|
| Name:                            | <b>Hassan A. Shora</b>             |
| Department, University & Country | <b>Port-Said university, Egypt</b> |